| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
- tern-601
- orforglipron
- Semaglutide
- gsbr-1290
- GLP-1치료제
- Efruxifermin
- 비만치료제
- GPCR
- Pegozafermin
- Viking Therapeutics
- Mash
- ct-996
- il-17 inhibitor
- 제약바이오
- VK2735
- GLP-1 치료제
- GLP-1
- CAR-T
- CAR-T in autoimmune
- 노보노디스크
- tirzepatide
- VKTX
- danuglipron
- 경구용 glp-1
- lilly
- Novo Nordisk
- Nash
- 바이오스터디
- glp-1 비만
- 자가면역질환 치료제
- Today
- Total
목록CRBU (2)
제약바이오 츄롸이츄롸이!~
Caribou Biosciences - 2024 ASCO update (2024-06-02)
https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-presents-encouraging-clinical-data-cb-010 Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous ..
2024-05-09 Fate Therapeutics 실적발표 + 2024 ASGCT 학회 자료 발표https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-first-quarter-2024-financial-results Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates | Fate Therapeutics, Inc.The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockho..